Observational Study; Clinical Effectiveness and Impact on Patient Reported Outcomes in Venezuelan Patients With Psoriasis After 16 Weeks of ADA Therapy

Trial Profile

Observational Study; Clinical Effectiveness and Impact on Patient Reported Outcomes in Venezuelan Patients With Psoriasis After 16 Weeks of ADA Therapy

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 26 Nov 2016 Planned End Date changed from 1 May 2016 to 1 Mar 2016.
    • 26 Nov 2016 Planned primary completion date changed from 1 May 2016 to 1 Mar 2016.
    • 26 Nov 2016 Status changed from discontinued to withdrawn prior to enrolment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top